‘Oncocheck’: an international external quality assessment scheme for immunoassays of tumor markers
Starting from November 1990, an international External Quality Assessment Scheme (EQAS) for immmunoassays of tumor markers has been organized. Presently, 238 laboratories from France, Germany, Italy, Japan and Spain participate in the scheme. In this report the main features of the EQAS and data pro...
Gespeichert in:
| Veröffentlicht in: | Nuclear medicine and biology 1994-04, Vol.21 (3), p.483-493 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 493 |
|---|---|
| container_issue | 3 |
| container_start_page | 483 |
| container_title | Nuclear medicine and biology |
| container_volume | 21 |
| creator | Cohen, Richard Zucchelli, Gian-Carlo Fraysse, Marc Pilo, Alessandro Rigault, Marie-Yolande Grillet, Serge Bizollon, Charles-Albert |
| description | Starting from November 1990, an international External Quality Assessment Scheme (EQAS) for immmunoassays of tumor markers has been organized. Presently, 238 laboratories from France, Germany, Italy, Japan and Spain participate in the scheme. In this report the main features of the EQAS and data processing are outlined. Results collected during the 1992- cycle allow evaluation of the state of the art of AFP, CEA, CA 19-9, CA 15-3, CA 125 and PSA immunoassays. According to their analytical performances, the 6 tumor marker immunoassays can be classified into several groups, the first including AFP and CA 15-3 for wich both total variability and within-kit agreement are good. For CEA assay, performance can be considered as satisfactory even though further improvements of between-lab agreement would be welcome. For the 3 other tumor markers, the higher total variability indicates an urgent need for a better standardization by improvement of either both within-kit and between-kit agreements (CA 19-9) or between-kit agreement mainly (PSA, CA 125). |
| doi_str_mv | 10.1016/0969-8051(94)90072-8 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_77105946</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>0969805194900728</els_id><sourcerecordid>77105946</sourcerecordid><originalsourceid>FETCH-LOGICAL-c417t-fb8a92ffdbc9b30799037fe82e32e57661f27906d13156cc819c6fc7516b9dd33</originalsourceid><addsrcrecordid>eNqFkc-OFCEQxonRrOPqG2jCwRg9tFINDY0HE7PxX7LJXvRMaLqIuN2wC93Gue1j6Ovtk8jsTOaoJwq-31ehviLkKbDXwEC-YVrqpmcdvNTilWZMtU1_j2ygr4WWIO6TzRF5SB6V8oNVmwB2Qk50ywVnekP87c3vi-iS-47u8vbmz1tqIw1xwRztElK0E8Vfd7eJXq92CsuW2lKwlBnjQkv1zUh9yjTM8xpT1ey20OTpss71dbb5EnN5TB54OxV8cjhPybePH76efW7OLz59OXt_3jgBamn80Fvdej8OTg-cKa0ZVx77FnmLnZISfKs0kyNw6KRzPWgnvVMdyEGPI-en5MW-71VO1yuWxcyhOJwmGzGtxSgFrNNC_hcEqRVApyoo9qDLqZSM3lzlUKfaGmBmtwezC9nsQjZamLs9mL7anh36r8OM49F0CL7qzw-6Lc5OPtvoQjliAmTH265i7_YY1tB-BsymuIDR4RgyusWMKfz7H38BLX6nGA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16971157</pqid></control><display><type>article</type><title>‘Oncocheck’: an international external quality assessment scheme for immunoassays of tumor markers</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Cohen, Richard ; Zucchelli, Gian-Carlo ; Fraysse, Marc ; Pilo, Alessandro ; Rigault, Marie-Yolande ; Grillet, Serge ; Bizollon, Charles-Albert</creator><contributor>Bizollon, CA</contributor><creatorcontrib>Cohen, Richard ; Zucchelli, Gian-Carlo ; Fraysse, Marc ; Pilo, Alessandro ; Rigault, Marie-Yolande ; Grillet, Serge ; Bizollon, Charles-Albert ; Bizollon, CA</creatorcontrib><description>Starting from November 1990, an international External Quality Assessment Scheme (EQAS) for immmunoassays of tumor markers has been organized. Presently, 238 laboratories from France, Germany, Italy, Japan and Spain participate in the scheme. In this report the main features of the EQAS and data processing are outlined. Results collected during the 1992- cycle allow evaluation of the state of the art of AFP, CEA, CA 19-9, CA 15-3, CA 125 and PSA immunoassays. According to their analytical performances, the 6 tumor marker immunoassays can be classified into several groups, the first including AFP and CA 15-3 for wich both total variability and within-kit agreement are good. For CEA assay, performance can be considered as satisfactory even though further improvements of between-lab agreement would be welcome. For the 3 other tumor markers, the higher total variability indicates an urgent need for a better standardization by improvement of either both within-kit and between-kit agreements (CA 19-9) or between-kit agreement mainly (PSA, CA 125).</description><identifier>ISSN: 0969-8051</identifier><identifier>EISSN: 1872-9614</identifier><identifier>DOI: 10.1016/0969-8051(94)90072-8</identifier><identifier>PMID: 9234309</identifier><language>eng</language><publisher>Amsterdam: Elsevier Inc</publisher><subject>Automatic Data Processing ; Biological and medical sciences ; Biomarkers, Tumor - analysis ; Europe ; Host-tumor relations. Immunology. Biological markers ; Humans ; Immunoassay - standards ; Immunoradiometric Assay ; International Cooperation ; Medical sciences ; Quality Assurance, Health Care ; Reagent Kits, Diagnostic ; Reproducibility of Results ; Tumors</subject><ispartof>Nuclear medicine and biology, 1994-04, Vol.21 (3), p.483-493</ispartof><rights>1994</rights><rights>1994 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c417t-fb8a92ffdbc9b30799037fe82e32e57661f27906d13156cc819c6fc7516b9dd33</citedby><cites>FETCH-LOGICAL-c417t-fb8a92ffdbc9b30799037fe82e32e57661f27906d13156cc819c6fc7516b9dd33</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/0969805194900728$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>309,310,314,776,780,785,786,3537,23909,23910,25118,27901,27902,65306</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=4165325$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9234309$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Bizollon, CA</contributor><creatorcontrib>Cohen, Richard</creatorcontrib><creatorcontrib>Zucchelli, Gian-Carlo</creatorcontrib><creatorcontrib>Fraysse, Marc</creatorcontrib><creatorcontrib>Pilo, Alessandro</creatorcontrib><creatorcontrib>Rigault, Marie-Yolande</creatorcontrib><creatorcontrib>Grillet, Serge</creatorcontrib><creatorcontrib>Bizollon, Charles-Albert</creatorcontrib><title>‘Oncocheck’: an international external quality assessment scheme for immunoassays of tumor markers</title><title>Nuclear medicine and biology</title><addtitle>Nucl Med Biol</addtitle><description>Starting from November 1990, an international External Quality Assessment Scheme (EQAS) for immmunoassays of tumor markers has been organized. Presently, 238 laboratories from France, Germany, Italy, Japan and Spain participate in the scheme. In this report the main features of the EQAS and data processing are outlined. Results collected during the 1992- cycle allow evaluation of the state of the art of AFP, CEA, CA 19-9, CA 15-3, CA 125 and PSA immunoassays. According to their analytical performances, the 6 tumor marker immunoassays can be classified into several groups, the first including AFP and CA 15-3 for wich both total variability and within-kit agreement are good. For CEA assay, performance can be considered as satisfactory even though further improvements of between-lab agreement would be welcome. For the 3 other tumor markers, the higher total variability indicates an urgent need for a better standardization by improvement of either both within-kit and between-kit agreements (CA 19-9) or between-kit agreement mainly (PSA, CA 125).</description><subject>Automatic Data Processing</subject><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Europe</subject><subject>Host-tumor relations. Immunology. Biological markers</subject><subject>Humans</subject><subject>Immunoassay - standards</subject><subject>Immunoradiometric Assay</subject><subject>International Cooperation</subject><subject>Medical sciences</subject><subject>Quality Assurance, Health Care</subject><subject>Reagent Kits, Diagnostic</subject><subject>Reproducibility of Results</subject><subject>Tumors</subject><issn>0969-8051</issn><issn>1872-9614</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1994</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc-OFCEQxonRrOPqG2jCwRg9tFINDY0HE7PxX7LJXvRMaLqIuN2wC93Gue1j6Ovtk8jsTOaoJwq-31ehviLkKbDXwEC-YVrqpmcdvNTilWZMtU1_j2ygr4WWIO6TzRF5SB6V8oNVmwB2Qk50ywVnekP87c3vi-iS-47u8vbmz1tqIw1xwRztElK0E8Vfd7eJXq92CsuW2lKwlBnjQkv1zUh9yjTM8xpT1ey20OTpss71dbb5EnN5TB54OxV8cjhPybePH76efW7OLz59OXt_3jgBamn80Fvdej8OTg-cKa0ZVx77FnmLnZISfKs0kyNw6KRzPWgnvVMdyEGPI-en5MW-71VO1yuWxcyhOJwmGzGtxSgFrNNC_hcEqRVApyoo9qDLqZSM3lzlUKfaGmBmtwezC9nsQjZamLs9mL7anh36r8OM49F0CL7qzw-6Lc5OPtvoQjliAmTH265i7_YY1tB-BsymuIDR4RgyusWMKfz7H38BLX6nGA</recordid><startdate>19940401</startdate><enddate>19940401</enddate><creator>Cohen, Richard</creator><creator>Zucchelli, Gian-Carlo</creator><creator>Fraysse, Marc</creator><creator>Pilo, Alessandro</creator><creator>Rigault, Marie-Yolande</creator><creator>Grillet, Serge</creator><creator>Bizollon, Charles-Albert</creator><general>Elsevier Inc</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QO</scope><scope>8FD</scope><scope>FR3</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>19940401</creationdate><title>‘Oncocheck’: an international external quality assessment scheme for immunoassays of tumor markers</title><author>Cohen, Richard ; Zucchelli, Gian-Carlo ; Fraysse, Marc ; Pilo, Alessandro ; Rigault, Marie-Yolande ; Grillet, Serge ; Bizollon, Charles-Albert</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c417t-fb8a92ffdbc9b30799037fe82e32e57661f27906d13156cc819c6fc7516b9dd33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1994</creationdate><topic>Automatic Data Processing</topic><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Europe</topic><topic>Host-tumor relations. Immunology. Biological markers</topic><topic>Humans</topic><topic>Immunoassay - standards</topic><topic>Immunoradiometric Assay</topic><topic>International Cooperation</topic><topic>Medical sciences</topic><topic>Quality Assurance, Health Care</topic><topic>Reagent Kits, Diagnostic</topic><topic>Reproducibility of Results</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Cohen, Richard</creatorcontrib><creatorcontrib>Zucchelli, Gian-Carlo</creatorcontrib><creatorcontrib>Fraysse, Marc</creatorcontrib><creatorcontrib>Pilo, Alessandro</creatorcontrib><creatorcontrib>Rigault, Marie-Yolande</creatorcontrib><creatorcontrib>Grillet, Serge</creatorcontrib><creatorcontrib>Bizollon, Charles-Albert</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Biotechnology Research Abstracts</collection><collection>Technology Research Database</collection><collection>Engineering Research Database</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nuclear medicine and biology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Cohen, Richard</au><au>Zucchelli, Gian-Carlo</au><au>Fraysse, Marc</au><au>Pilo, Alessandro</au><au>Rigault, Marie-Yolande</au><au>Grillet, Serge</au><au>Bizollon, Charles-Albert</au><au>Bizollon, CA</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>‘Oncocheck’: an international external quality assessment scheme for immunoassays of tumor markers</atitle><jtitle>Nuclear medicine and biology</jtitle><addtitle>Nucl Med Biol</addtitle><date>1994-04-01</date><risdate>1994</risdate><volume>21</volume><issue>3</issue><spage>483</spage><epage>493</epage><pages>483-493</pages><issn>0969-8051</issn><eissn>1872-9614</eissn><abstract>Starting from November 1990, an international External Quality Assessment Scheme (EQAS) for immmunoassays of tumor markers has been organized. Presently, 238 laboratories from France, Germany, Italy, Japan and Spain participate in the scheme. In this report the main features of the EQAS and data processing are outlined. Results collected during the 1992- cycle allow evaluation of the state of the art of AFP, CEA, CA 19-9, CA 15-3, CA 125 and PSA immunoassays. According to their analytical performances, the 6 tumor marker immunoassays can be classified into several groups, the first including AFP and CA 15-3 for wich both total variability and within-kit agreement are good. For CEA assay, performance can be considered as satisfactory even though further improvements of between-lab agreement would be welcome. For the 3 other tumor markers, the higher total variability indicates an urgent need for a better standardization by improvement of either both within-kit and between-kit agreements (CA 19-9) or between-kit agreement mainly (PSA, CA 125).</abstract><cop>Amsterdam</cop><pub>Elsevier Inc</pub><pmid>9234309</pmid><doi>10.1016/0969-8051(94)90072-8</doi><tpages>11</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0969-8051 |
| ispartof | Nuclear medicine and biology, 1994-04, Vol.21 (3), p.483-493 |
| issn | 0969-8051 1872-9614 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_77105946 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Automatic Data Processing Biological and medical sciences Biomarkers, Tumor - analysis Europe Host-tumor relations. Immunology. Biological markers Humans Immunoassay - standards Immunoradiometric Assay International Cooperation Medical sciences Quality Assurance, Health Care Reagent Kits, Diagnostic Reproducibility of Results Tumors |
| title | ‘Oncocheck’: an international external quality assessment scheme for immunoassays of tumor markers |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-04T00%3A43%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=%E2%80%98Oncocheck%E2%80%99:%20an%20international%20external%20quality%20assessment%20scheme%20for%20immunoassays%20of%20tumor%20markers&rft.jtitle=Nuclear%20medicine%20and%20biology&rft.au=Cohen,%20Richard&rft.date=1994-04-01&rft.volume=21&rft.issue=3&rft.spage=483&rft.epage=493&rft.pages=483-493&rft.issn=0969-8051&rft.eissn=1872-9614&rft_id=info:doi/10.1016/0969-8051(94)90072-8&rft_dat=%3Cproquest_cross%3E77105946%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16971157&rft_id=info:pmid/9234309&rft_els_id=0969805194900728&rfr_iscdi=true |